In a study by Treanor et al.,86 the JAK inhibitor ruxolitinib prolonged the survival of mice with ETP-ALL resulting from Il-7r mutations but failed to induce a significant anti-leukaemic response. Here, IL7R is linked to acute lymphoblastic leukemia.